Nicotine therapeutic benefits: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(added ptsd)
Line 15: Line 15:




==ADD/ADHD==


===2011 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353150/ Cognitive enhancers for the treatment of ADHD]===
*Attention deficit hyperactivity disorder (ADHD) is one of the most common psychiatric disorders, affecting approximately 8–9% of school-aged children and 4–5% of adults (Froehlich et al., 2007; Kessler et al., 2006; Visser et al., 2007). Although formally the disorder is characterized by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity (APA, 2000), myriad phenotypic features—many of which are related to cognition broadly defined—have been shown to distinguish those with ADHD from those without the disorder.
*Together, these findings have led to the hypothesis that individuals with ADHD may smoke in order to alleviate requisite symptoms of the disorder and further suggest nicotine and/or nicotinic agonists can be used to improve aspects of cognitive function in these patients (McClernon and Kollins, 2008). Some support for this hypothesis has been provided by studies which have shown positive effects of nicotine on ADHD symptoms (Gehricke et al., 2009; Shytle et al., 2002) and cognitive performance (Levin et al., 1996; Potter and Newhouse, 2004) in non-smokers with ADHD. Whereas there are currently no FDA-approved nicotinic agonists to treat ADHD, laboratory and small-scale clinical trials have been conducted in recent years, and novel nicotinic pharmacotherapies are on the horizon.
===2008 [https://www.sciencedirect.com/science/article/abs/pii/S0091305707003048?via%3Dihub Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder]===
*Non-smoking young adults with ADHD-C showed improvements in cognitive performance following nicotine administration in several domains that are central to [[Abbreviations|'''ADHD''']].
*[https://sci-hub.st/https://doi.org/10.1016/j.pbb.2007.09.014 PDF Version]
*Citation: Alexandra S. Potter, Paul A. Newhouse, Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder, Pharmacology Biochemistry and Behavior, Volume 88, Issue 4, 2008, Pages 407-417, ISSN 0091-3057, doi: 10.1016/j.pbb.2007.09.014.
*Acknowledgements: This work was supported by: GCRC M01-00109 and Targacept Inc.
*Keywords: Nicotine, Cholinergic, ADHD, Cognition, Behavioral inhibition, Delay aversion, Methylphenidate, Stop Signal Task, Impulsivity
===2006 [https://www.sciencedirect.com/science/article/abs/pii/S0031938405005627?via%3Dihub Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits]===
*The results showed nicotine-induced improvement on some measures of sustained attention in the low attention group and some decrement in working memory in the high attention group, which suggests that nicotine tends to optimize rather than improve performance on cognitive tasks.
*[https://sci-hub.st/https://doi.org/10.1016/j.physbeh.2005.12.011 PDF Version]
*Citation: D.V. Poltavski, T. Petros, Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits, Physiology & Behavior, Volume 87, Issue 3, 2006, Pages 614-624, ISSN 0031-9384, doi: 10.1016/j.physbeh.2005.12.011.
*Keywords: ADHD, Transdermal nicotine, CPT, WCST, Stroop, Attention, Memory


==Addiction==
==Addiction==
Line 307: Line 290:


==HIV/AIDS==
==HIV/AIDS==
==Mental Health - ADD/ADHD==
*[https://www.nami.org/About-Mental-Illness/Mental-Health-Conditions/ADHD Attention Deficit Hyperactivity Disorder (ADHD) - Information from NAMI]
*[https://www.understood.org/en/learning-thinking-differences/child-learning-disabilities/add-adhd/is-adhd-a-mental-illness Is ADHD a mental illness?]
**Mental illness is a very broad term. It refers to any type of condition that affects a person’s behavior, mood, or thinking.
**Technically a mental illness, few practitioners use the words “mental illness” to describe kids with ADHD. They tend to refer to it as a “behavior disorder.” Some might even refer to it as a learning difference that can affect all areas of learning.
*[https://www.understood.org/en/learning-thinking-differences/child-learning-disabilities/add-adhd/difference-between-add-adhd The difference between ADD and ADHD]
===2011 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353150/ Cognitive enhancers for the treatment of ADHD]===
*Attention deficit hyperactivity disorder (ADHD) is one of the most common psychiatric disorders, affecting approximately 8–9% of school-aged children and 4–5% of adults (Froehlich et al., 2007; Kessler et al., 2006; Visser et al., 2007). Although formally the disorder is characterized by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity (APA, 2000), myriad phenotypic features—many of which are related to cognition broadly defined—have been shown to distinguish those with ADHD from those without the disorder.
*Together, these findings have led to the hypothesis that individuals with ADHD may smoke in order to alleviate requisite symptoms of the disorder and further suggest nicotine and/or nicotinic agonists can be used to improve aspects of cognitive function in these patients (McClernon and Kollins, 2008). Some support for this hypothesis has been provided by studies which have shown positive effects of nicotine on ADHD symptoms (Gehricke et al., 2009; Shytle et al., 2002) and cognitive performance (Levin et al., 1996; Potter and Newhouse, 2004) in non-smokers with ADHD. Whereas there are currently no FDA-approved nicotinic agonists to treat ADHD, laboratory and small-scale clinical trials have been conducted in recent years, and novel nicotinic pharmacotherapies are on the horizon.
===2008 [https://www.sciencedirect.com/science/article/abs/pii/S0091305707003048?via%3Dihub Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder]===
*Non-smoking young adults with ADHD-C showed improvements in cognitive performance following nicotine administration in several domains that are central to [[Abbreviations|'''ADHD''']].
*[https://sci-hub.st/https://doi.org/10.1016/j.pbb.2007.09.014 PDF Version]
*Citation: Alexandra S. Potter, Paul A. Newhouse, Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder, Pharmacology Biochemistry and Behavior, Volume 88, Issue 4, 2008, Pages 407-417, ISSN 0091-3057, doi: 10.1016/j.pbb.2007.09.014.
*Acknowledgements: This work was supported by: GCRC M01-00109 and Targacept Inc.
*Keywords: Nicotine, Cholinergic, ADHD, Cognition, Behavioral inhibition, Delay aversion, Methylphenidate, Stop Signal Task, Impulsivity
===2006 [https://www.sciencedirect.com/science/article/abs/pii/S0031938405005627?via%3Dihub Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits]===
*The results showed nicotine-induced improvement on some measures of sustained attention in the low attention group and some decrement in working memory in the high attention group, which suggests that nicotine tends to optimize rather than improve performance on cognitive tasks.
*[https://sci-hub.st/https://doi.org/10.1016/j.physbeh.2005.12.011 PDF Version]
*Citation: D.V. Poltavski, T. Petros, Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits, Physiology & Behavior, Volume 87, Issue 3, 2006, Pages 614-624, ISSN 0031-9384, doi: 10.1016/j.physbeh.2005.12.011.
*Keywords: ADHD, Transdermal nicotine, CPT, WCST, Stroop, Attention, Memory




Line 315: Line 326:


==Mental Health - Behavior Issues==
==Mental Health - Behavior Issues==
*See Also: Mental Health - ADD/ADHD above


===2020 [https://www.sciencedirect.com/science/article/abs/pii/S0028390819305003?via%3Dihub Regulation of aggressive behaviors by nicotinic acetylcholine receptors: Animal models, human genetics, and clinical studies]===
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S0028390819305003?via%3Dihub Regulation of aggressive behaviors by nicotinic acetylcholine receptors: Animal models, human genetics, and clinical studies]===
Line 323: Line 336:
*Acknowledgements: This work was supported by National Institutes of Health grants MH116339 (A.S.L.), MH077681 and DA14241 (M.R.P.).
*Acknowledgements: This work was supported by National Institutes of Health grants MH116339 (A.S.L.), MH077681 and DA14241 (M.R.P.).
*Keywords: Nicotine, Nicotinic receptor, Aggression, Aggressive behavior, Impulsivity, Acetylcholine
*Keywords: Nicotine, Nicotinic receptor, Aggression, Aggressive behavior, Impulsivity, Acetylcholine


===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394231/ An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder]===
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394231/ An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder]===
Line 335: Line 349:


==Mental Health - Depression==
==Mental Health - Depression==


===2018 [https://pubmed.ncbi.nlm.nih.gov/29795403/ Nicotine normalizes cortico-striatal connectivity in non-smoking individuals with major depressive disorder]===
===2018 [https://pubmed.ncbi.nlm.nih.gov/29795403/ Nicotine normalizes cortico-striatal connectivity in non-smoking individuals with major depressive disorder]===
Line 341: Line 356:
*Citation: Janes AC, Zegel M, Ohashi K, Betts J, Molokotos E, Olson D, Moran L, Pizzagalli DA. Nicotine normalizes cortico-striatal connectivity in non-smoking individuals with major depressive disorder. Neuropsychopharmacology. 2018 Nov;43(12):2445-2451. doi: 10.1038/s41386-018-0069-x. Epub 2018 Apr 19. PMID: 29795403; PMCID: PMC6180119.
*Citation: Janes AC, Zegel M, Ohashi K, Betts J, Molokotos E, Olson D, Moran L, Pizzagalli DA. Nicotine normalizes cortico-striatal connectivity in non-smoking individuals with major depressive disorder. Neuropsychopharmacology. 2018 Nov;43(12):2445-2451. doi: 10.1038/s41386-018-0069-x. Epub 2018 Apr 19. PMID: 29795403; PMCID: PMC6180119.
*Acknoledgements: This project was supported by the National Institute on Drug Abuse grants K10 DA029645 and K02 DA042987 (ACJ). DAP was partially supported by National Institute of Mental Health grant R37 MH068376. Over the past 3 years, DAP has received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Pfizer and Posit Science, for activities unrelated to the current research.
*Acknoledgements: This project was supported by the National Institute on Drug Abuse grants K10 DA029645 and K02 DA042987 (ACJ). DAP was partially supported by National Institute of Mental Health grant R37 MH068376. Over the past 3 years, DAP has received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Pfizer and Posit Science, for activities unrelated to the current research.


===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129985/ Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Non-Smokers with Late-Life Depression]===
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129985/ Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Non-Smokers with Late-Life Depression]===
Line 348: Line 364:
*Citation: Gandelman JA, Kang H, Antal A, Albert K, Boyd BD, Conley AC, Newhouse P, Taylor WD. Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Nonsmokers With Late-Life Depression. J Clin Psychiatry. 2018 Aug 28;79(5):18m12137. doi: 10.4088/JCP.18m12137. PMID: 30192444; PMCID: PMC6129985.
*Citation: Gandelman JA, Kang H, Antal A, Albert K, Boyd BD, Conley AC, Newhouse P, Taylor WD. Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Nonsmokers With Late-Life Depression. J Clin Psychiatry. 2018 Aug 28;79(5):18m12137. doi: 10.4088/JCP.18m12137. PMID: 30192444; PMCID: PMC6129985.
*Acknowledgements: This research was supported by NIH grant K24 MH110598 and CTSA award UL1TR000445 from the National Center for Advancing Translational Sciences. The sponsor provided funding for the study but did not influence the design or conduct of the study.
*Acknowledgements: This research was supported by NIH grant K24 MH110598 and CTSA award UL1TR000445 from the National Center for Advancing Translational Sciences. The sponsor provided funding for the study but did not influence the design or conduct of the study.


===2002 [https://pubmed.ncbi.nlm.nih.gov/11995405/ Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients]===
===2002 [https://pubmed.ncbi.nlm.nih.gov/11995405/ Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients]===
*Acute administration of nicotine patches produced rapid eye movement sleep (REM) increases in non-smoking major depressed patients as well as clinical improvement in mood. Antidepressant effect was also observed after four continuous days of nicotine administration.
*Acute administration of nicotine patches produced rapid eye movement sleep (REM) increases in non-smoking major depressed patients as well as clinical improvement in mood. Antidepressant effect was also observed after four continuous days of nicotine administration.
*Citation: Salin-Pascual RJ. Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients. Rev Invest Clin. 2002 Jan-Feb;54(1):36-40. PMID: 11995405.
*Citation: Salin-Pascual RJ. Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients. Rev Invest Clin. 2002 Jan-Feb;54(1):36-40. PMID: 11995405.


===1999 [https://link.springer.com/article/10.1007/s002130050879 Antidepressant effects of nicotine in an animal model of depression]===
===1999 [https://link.springer.com/article/10.1007/s002130050879 Antidepressant effects of nicotine in an animal model of depression]===
Line 361: Line 379:
*Acknowledgements This work was supported in part by the Department of Pharmacology, Howard University, VAMC and Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
*Acknowledgements This work was supported in part by the Department of Pharmacology, Howard University, VAMC and Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
*Keywords: Key words Nicotine · Nicotinic receptor · FSL and FRL rats · Animal model of depression  
*Keywords: Key words Nicotine · Nicotinic receptor · FSL and FRL rats · Animal model of depression  


===1998 [https://pubmed.ncbi.nlm.nih.gov/9592048/ A novel effect of nicotine on mood and sleep in major depression]===
===1998 [https://pubmed.ncbi.nlm.nih.gov/9592048/ A novel effect of nicotine on mood and sleep in major depression]===
Line 367: Line 386:
*Salín-Pascual RJ, Drucker-Colín R. A novel effect of nicotine on mood and sleep in major depression. Neuroreport. 1998 Jan 5;9(1):57-60. doi: 10.1097/00001756-199801050-00012. PMID: 9592048.
*Salín-Pascual RJ, Drucker-Colín R. A novel effect of nicotine on mood and sleep in major depression. Neuroreport. 1998 Jan 5;9(1):57-60. doi: 10.1097/00001756-199801050-00012. PMID: 9592048.
*ACKNOWLEDGEMENT: This work has been supported by the following grants: DGAPA-UNAM IN -200895 to R.J.S-P.
*ACKNOWLEDGEMENT: This work has been supported by the following grants: DGAPA-UNAM IN -200895 to R.J.S-P.


===1996 [https://pubmed.ncbi.nlm.nih.gov/9746444/ Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression]===
===1996 [https://pubmed.ncbi.nlm.nih.gov/9746444/ Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression]===
Line 372: Line 392:
*Results of the visual analog scale and [[Abbreviations|'''HAM-D''']] showed a significant improvement in depression after the second day of nicotine patches.
*Results of the visual analog scale and [[Abbreviations|'''HAM-D''']] showed a significant improvement in depression after the second day of nicotine patches.
*Citation: Salín-Pascual RJ, Rosas M, Jimenez-Genchi A, Rivera-Meza BL, Delgado-Parra V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J Clin Psychiatry. 1996 Sep;57(9):387-9. PMID: 9746444.
*Citation: Salín-Pascual RJ, Rosas M, Jimenez-Genchi A, Rivera-Meza BL, Delgado-Parra V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J Clin Psychiatry. 1996 Sep;57(9):387-9. PMID: 9746444.


===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]===
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]===
Line 378: Line 399:
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.
==Mental Health - PTSD (Post Traumatic Stress Disorder==
===2012 [https://www.hindawi.com/journals/aps/2012/265724/ Effects of Nicotine on Emotional Reactivity in PTSD and Non-PTSD Smokers: Results of a Pilot fMRI Study]===
*Smokers with PTSD report greater NA (Negative Affects) immediately prior to smoking and greater decreases in NA following smoking, and these findings are consistent with the observed patterns of brain activation in the current study. Thus, our findings provide a neurobiological basis that helps explain why individuals with PTSD are at greater risk of smoking and also experience greater difficulty quitting. The present study is not without its limitations. Our sample size was small and was predominately represented by female smokers.
*[https://downloads.hindawi.com/journals/aps/2012/265724.pdf PDF Version]
*Citation: Froeliger, B., Crowell Beckham, J., Feldman Dennis, M., Victoria Kozink, R., & Joseph McClernon, F. (2012). Effects of Nicotine on Emotional Reactivity in PTSD and Non-PTSD Smokers: Results of a Pilot fMRI Study. Advances in Pharmacological Sciences, 2012, 1–6. doi:10.1155/2012/265724
*Acknowledgement: Department of Veterans Affairs or the National Institutes of Health.






==Mental Health - Schizophrenia==
==Mental Health - Schizophrenia==


===2020 [https://www.sciencedirect.com/science/article/abs/pii/S0149763420305042?via%3Dihub The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review]===
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S0149763420305042?via%3Dihub The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review]===
Line 388: Line 420:
*Citation: Clément Dondé, Jérôme Brunelin, Marine Mondino, Caroline Cellard, Benjamin Rolland, Frédéric Haesebaert, The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review, Neuroscience & Biobehavioral Reviews, Volume 118, 2020, Pages 121-133, ISSN 0149-7634, doi: 10.1016/j.neubiorev.2020.07.035.
*Citation: Clément Dondé, Jérôme Brunelin, Marine Mondino, Caroline Cellard, Benjamin Rolland, Frédéric Haesebaert, The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review, Neuroscience & Biobehavioral Reviews, Volume 118, 2020, Pages 121-133, ISSN 0149-7634, doi: 10.1016/j.neubiorev.2020.07.035.
*Keywords: Schizophrenia, Nicotine, Cognition, Early sensory
*Keywords: Schizophrenia, Nicotine, Cognition, Early sensory


===2009 [https://pubmed.ncbi.nlm.nih.gov/19328631/ Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications]===
===2009 [https://pubmed.ncbi.nlm.nih.gov/19328631/ Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications]===
Line 397: Line 430:


==Movement Disorders (not diagnosis specific)==
==Movement Disorders (not diagnosis specific)==


===2014 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149916/ Role for the nicotinic cholinergic system in movement disorders; therapeutic implications]===
===2014 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149916/ Role for the nicotinic cholinergic system in movement disorders; therapeutic implications]===
Retrieved from ‘https://safernicotine.wiki/mediawiki/index.php/Nicotine_therapeutic_benefits’